Investigational New Drugs

Published by: Springer  

People

  1. Antonescu
    Antonescu
  2. Chi
    Chi
  3. D'Angelo
    D'Angelo
  4. Danila
    Danila
  5. Dickson
    Dickson
  6. Francis
    Francis
  7. Goldfarb
    Goldfarb
  8. Gounder
    Gounder
  9. Harding
    Harding
  10. Heinemann
    Heinemann

Groups

  1. Department of Medicine (5)
  2. Solid Tumor Oncology Division (5)
  3. Epidemiology and Biostatistics (2)
  4. Gastrointestinal Oncology Service (2)
  5. Hematologic Malignancies, Division of (2)
  6. Biostatistics Service (1)
  7. Body Imaging Service (1)
  8. Breast Medicine Service (1)
  9. Center for Pancreatic Cancer Research (1)
  10. Dermatology Service (1)
Search Within
  1. "2019"
Formats
  1. Journal Article (5)
Groups
  1. Department of Medicine (5)
  2. Solid Tumor Oncology Division (5)
  3. Epidemiology and Biostatistics (2)
  4. Gastrointestinal Oncology Service (2)
  5. Hematologic Malignancies, Division of (2)
  6. Biostatistics Service (1)

More Groups

People
  1. Alexander Shoushtari (1)
  2. Ana Sjoberg (1)
  3. Chloe Mcfadyen (1)
  4. Ciara Kelly (1)
  5. Cristina Antonescu (1)
  6. Dana Rathkopf (1)

More People

Years
  1. 2019 (5)
Publishers
  1. Springer (5)

Results (5)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A randomized phase 2 trial of the efficacy and safety of a novel topical povidone-iodine formulation for cancer therapy-associated paronychia
    Journal Article

    Capriotti, K. D.; Anadkat, M.; Choi, J.; Kaffenberger, B.; McLellan, B.; Barone, S.; Kukoyi, O.; Goldfarb, S.; Lacouture, M.
    Investigational New Drugs (2019)

    Fulltext@MSK | Save
  • A phase I study of the antibody drug conjugate ASG-5ME, an SLC44A4-targeting antibody carrying auristatin E, in metastatic castration-resistant prostate cancer
    Journal Article

    McHugh, D.; Eisenberger, M.; Heath, E. I.; Bruce, J.; Danila, D. C.; Rathkopf, D. E.; Feldman, J.; Slovin, S. F.; Anand, B.; Chu, R.; more...
    Investigational New Drugs (2019)

    Fulltext@MSK | Save
  • A phase II study of the orally administered negative enantiomer of gossypol (AT-101), a BH3 mimetic, in patients with advanced adrenal cortical carcinoma
    Journal Article

    Xie, H.; Yin, J.; Shah, M. H.; Menefee, M. E.; Bible, K. C.; Reidy-Lagunes, D.; Kane, M. A.; Quinn, D. I.; Gandara, D. R.; Erlichman, C.; more...
    Investigational New Drugs (2019)

    Fulltext@MSK | Save
  • A phase Ib study of BGJ398, a pan-FGFR kinase inhibitor in combination with imatinib in patients with advanced gastrointestinal stromal tumor
    Journal Article

    Kelly, C. M.; Shoushtari, A. N.; Qin, L. X.; D’Angelo, S. P.; Dickson, M. A.; Gounder, M. M.; Keohan, M. L.; Mcfadyen, C.; Sjoberg, A.; Singer, S.; more...
    Investigational New Drugs (2019)

    Fulltext@MSK | Save
  • Characterization and phase I study of CLR457, an orally bioavailable pan-class I PI3-kinase inhibitor
    Journal Article

    Harding, J. J.; Bauer, T. M.; Tan, D. S. W.; Bedard, P. L.; Rodon, J.; Doi, T.; Schnell, C.; Iyer, V.; Baffert, F.; Radhakrishnan, R.; more...
    Investigational New Drugs (2019)

    Fulltext@MSK | Save

    • Investigational New Drugs – authorized name for:

    Name ISSN / ISBN Publisher
    Investigational New Drugs 01676997 Springer Science + Business Media, LLC
    Investigational New Drugs 0167-6997 Unknown
    Investigational New Drugs 01676997 2023, The Author(s), Under Exclusive Licence To Springer Science+business Media, Llc, Part of Springer Nature
    Investigational New Drugs 01676997 Kluwer Academic Publishers
    Investigational New Drugs 0167-6997 Springer
    Investigational New Drugs 0167-6997 Springer
    Investigational New Drugs 01676997 Springer
    Investigational New Drugs 0167-6997 Kluwer Academic Publishers
    Investigational New Drugs 01676997 Springer Science + Business Media, LLC
    Investigational New Drugs 0167-6997 Martinus Nijhoff Publishers
    Investigational New Drugs 01676997 2020, The Author(s)
    Investigational New Drugs 0167-6997 Springer
    Investigational New Drugs 0167-6997 Springer
    Investigational New Drugs 15730646 Springer Science + Business Media, LLC
    Investigational New Drugs 0167-6997 Springer
    Investigational New Drugs 0167-6997 Springer
    Investigational New Drugs 15730646 Unknown
    Investigational New Drugs 0167-6997 Springer
    Investigational New Drugs 0167-6997 Springer
    Investigational New Drugs 15730646 Springer Science + Business Media, LLC
    Investigational New Drugs 01676997 2019, Springer Science+business Media, Llc, Part of Springer Nature
    Investigational New Drugs 01676997 2019, The Author(s)
    Investigational New Drugs 01676997 Springer Science + Business Media, LLC
    Investigational New Drugs 01676997 Springer Science + Business Media, LLC
    Investigational New Drugs 0167-6997 Springer
    Investigational New Drugs 0167-6997 Springer
    Investigational New Drugs 01676997 Unknown
    Investigational New Drugs 0167-6997 Springer
    Investigational New Drugs 01676997 Springer Science + Business Media, LLC
    Investigational New Drugs 0167-6997 Springer
    Investigational New Drugs 01676997 2017, Springer Science+business Media New York
    Investigational New Drugs 01676997 Springer Science + Business Media, LLC
    Investigational New Drugs 0167-6997 Springer Nature
    Investigational New Drugs 01676997 Springer Science+Business Media New York
    Investigational New Drugs 01676997 The Author(s)
    Investigational New Drugs 01676997 Springer
    Investigational New Drugs 01676997 2018, The Author(s)
    Investigational New Drugs 0167-6997 Springer
    Investigational New Drugs 0167-6997 Kluwer Academic Publishers
    Investigational New Drugs: An Interdisciplinary Journal for Clinicians and Scientists 01676997 Unknown